Clinical Trials Logo

Clinical Trial Summary

Although,bismuth-containing quadruple therapy has been highly recommended as first-line treatment regimen for H.pylori infection,it also has its problems and limitations in China.The primary resistance rates of metronidazole,clarithromycin and levofloxacin are all high in China.Besides that,tetracycline cannot be obtained and its complicated administration (four times daily) easily reduce patient compliance. In this study, we proposed to evaluate the eradication rate, safety, and compliance of a minocycline-based bismuth quadruple regimen.


Clinical Trial Description

A total of 339 H. pylori-infected, treatment-naive patients will be enrolled in this randomized controlled clinical trial. Patients will be randomly allocated into 3 groups: Esomeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 14 days; Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 14 days; Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 10 days. Eradication rates will be assessed 4-12 weeks after treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04558502
Study type Interventional
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Yan Li, master
Phone 15906698496
Email liyan_8786@zju.edu.cn
Status Not yet recruiting
Phase Phase 4
Start date January 5, 2022
Completion date December 5, 2022

See also
  Status Clinical Trial Phase
Completed NCT02873065 - Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori Phase 4
Recruiting NCT06349486 - Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication N/A
Completed NCT03924375 - Serum Pepsinogen After H. Pylori Eradication
Recruiting NCT04034641 - Effect of Probiotics on Helicobacter Pylori Eradication Phase 4
Completed NCT04850209 - The Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori N/A
Completed NCT06101420 - Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication Phase 3
Recruiting NCT06088316 - Efficacy of Amoxicillin-Esomeprazole HDDT Compared to Levofloxacin Triple Therapy for H. Pylori Eradication: A RCT Phase 4
Recruiting NCT05850117 - Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p N/A
Recruiting NCT05191888 - 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy Phase 4
Recruiting NCT05870397 - Optimal Recheck Time for Helicobacter Pylori Eradication: A Prospective Randomized Trial N/A